Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints
نویسندگان
چکیده
Recent advances in cardiovascular magnetic resonance (CMR) now allow the accurate and reproducible measurement of many aspects of cardiac and vascular structure and function, with prognostic data emerging for several key imaging biomarkers. These biomarkers are increasingly used in the evaluation of new drugs, devices and lifestyle modifications for the prevention and treatment of cardiovascular disease. This review outlines a conceptual framework for the application of imaging biomarkers to clinical trials, highlights several important CMR techniques which are in use in randomised studies, and reviews certain aspects of trial design, conduct and interpretation in relation to the use of CMR.
منابع مشابه
You get what you measure: evaluating endpoints in MS clinical trials.
Neurology 2008;71:620–621 Since the emergence of the modern therapeutic era in multiple sclerosis (MS), the field has focused on identifying agents to prevent long-term disability progression. In lieu of measuring the true endpoint of interest, long-term disability progression, clinical trials typically measure surrogate endpoints, such as short-term disability progression or changes in lesion ...
متن کاملBiomarkers in the prevention and treatment of atherosclerosis: need, validation, and future.
Cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality in the developed world, and there is a clear need to develop novel therapeutic strategies to reduce cardiovascular risk further than is currently possible. Traditionally, the effectiveness of new cardiovascular drugs has been evaluated in clinical trials using cardiovascular outcomes as endpoints. However,...
متن کاملTwo Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
BACKGROUND Surrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes. METHODS AND RESULTS We identified cardiovascular trials with primary surrogate endpoints published in the New England Journal of Medicine, Lancet, and JAMA: Journal of the American Medical Association from 1...
متن کاملCarotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors
BACKGROUND: Surrogate measures for cardiovascular disease events have the potential to increase greatly the efficiency of clinical trials. A leading candidate for such a surrogate is the progression of intima-media thickness (IMT) of the carotid artery; much experience has been gained with this endpoint in trials of HMG-CoA reductase inhibitors (statins). METHODS AND RESULTS: We examine two sep...
متن کاملAtherosclerosis imaging in progression/regression trials: surrogate marker or direct window into the atherosclerotic disease process?
CAD remains a major global cause of morbidity and mortality. Comprehensive drug development programs of novel pharmacological treatment strategies frequently utilize traditional mortality/morbidity endpoints studies and additional surrogate endpoints trials. This parallel approach allows an assessment of efficacy several years in advance of the availability of data from clinical endpoint trials...
متن کامل